Mitsubishi Tanabe Pharma America Inc (MTPA), a subsidiary of Japan-based Mitsubishi Tanabe Pharma Corporation (MTPC), announced on Monday that it has changed its corporate name to Tanabe Pharma America Inc (TPA), effective immediately.
In July, MTPC said that it would change name to Tanabe Pharma Corporation, effective 1 December 2025, following its acquisition by private investment firm Bain Capital.
TPA will continue to pursue a robust pipeline of products for hard-to-treat diseases, including neurodegenerative diseases, inflammatory, and metabolic conditions, the company said.
Sanofi and Regeneron's Dupixent gains Japan approval for paediatric asthma patients aged 6 to 11
Aqualung Therapeutics' Phase 2a lung fibrosis study approved by US FDA
Alvotech launches first-in-market golimumab biosimilar in Europe
Physiomics secures follow-on UK contract for Phase 2 study support
RedHill Biopharma reports positive opaganib data in venetoclax-resistant CLL
InduPro secures strategic investment and collaboration with Sanofi to advance autoimmune therapy
Innovent Biologics reports first participant dosed in Phase 1 trial of IBI3011
LabGenius and Sanofi launch AI-driven collaboration on antibody optimisation
Mitsubishi Tanabe Pharma America changes name
Sanofi and Regeneron's Dupixent approved in EU for chronic spontaneous urticaria
Xenogenic Materials Demonstrate Promising Results in Peri-Implantitis Management
European Commission approves Celltrion's Remsima IV liquid formulation
Biotheryx completes enrolment in ongoing Phase 1a trial of BTX-9341 for HR+/HER2- breast cancer
Henlius and Organon secure first US approval for pertuzumab biosimilar POHERDY